CervoMed CEO spouse granted 75,000 stock options

CervoMed Inc. reported an indirect insider award linked to director and 10% owner Sylvie Gregoire.

Rhea-AI Filing Summary

CervoMed Inc. reported an indirect insider award linked to director and 10% owner Sylvie Gregoire. A derivative position of 75,000 stock options with a $4.80 exercise price was granted on February 11, 2026 to her spouse, John Alam, the company’s President & Chief Executive Officer.

The options relate to 75,000 shares of common stock and were reported at a cost of $0 for the derivative itself, with 75,000 derivative securities beneficially owned after the transaction as indirect ownership "By Spouse." The filing states that Gregoire disclaims beneficial ownership. The underlying shares will vest in 36 monthly installments beginning February 28, 2026.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Gregoire Sylvie

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	75,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 75,000 contracts (Indirect, By Spouse)

Footnotes (2)

1. F1. Consists of an option to purchase shares of common stock granted to John Alam, M.D., the Reporting Person's spouse and the President & Chief Executive Officer of the Issuer and a member of its Board of Directors. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
2. F2. The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.

FAQ

What insider transaction did CervoMed (CRVO) disclose in this Form 4?

CervoMed disclosed a grant of 75,000 stock options with a $4.80 exercise price to CEO John Alam, reported as indirect ownership "By Spouse" for director and 10% owner Sylvie Gregoire. The derivative itself was reported at a price of $0.

Who is the reporting person in the CervoMed (CRVO) Form 4 filing?

The reporting person is Sylvie Gregoire, identified as both a director and a 10% owner of CervoMed. The award, however, consists of stock options granted to her spouse, CEO John Alam, and the filing states that Gregoire disclaims beneficial ownership of these securities.

How many CervoMed (CRVO) stock options were granted and at what price?

The filing reports 75,000 stock options relating to CervoMed common stock with a $4.80 exercise price per share. The derivative security itself was recorded at a price of $0, and 75,000 derivative securities are shown as beneficially owned following the transaction.

How do the CervoMed (CRVO) options granted to the CEO’s spouse vest?

The underlying CervoMed common shares vest in 36 equal, or nearly equal, monthly installments. Vesting occurs on the last calendar day of each month over a 36‑month period, beginning on February 28, 2026, according to the Form 4 footnote disclosure.

Does Sylvie Gregoire claim beneficial ownership of the CervoMed (CRVO) options?

No. The Form 4 states that the option grant consists of securities awarded to her spouse, CEO John Alam, and that Sylvie Gregoire disclaims beneficial ownership. The report clarifies it should not be deemed an admission of beneficial ownership for any Section 16 purpose.

What type of transaction code is used in the CervoMed (CRVO) Form 4?

The transaction is coded "A" for an acquisition, indicating a grant, award, or other acquisition of derivative securities. It covers a stock option (right to buy) tied to 75,000 CervoMed common shares, reported as indirect ownership through the reporting person’s spouse.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gregoire Sylvie

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	$4.8	02/11/2026		A		75,000		(2)	02/11/2036	Common Stock	75,000	$0	75,000	I	By Spouse

Explanation of Responses:

1. Consists of an option to purchase shares of common stock granted to John Alam, M.D., the Reporting Person's spouse and the President & Chief Executive Officer of the Issuer and a member of its Board of Directors. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

2. The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.